Active Ingredient History
Pomalidomide is a derivative of thalidomide marketed by Celgene, an analogue of thalidomide, is an immunomodulatory agent with antineoplastic activity. In in vitro cellular assays, pomalidomide inhibited proliferation and induced apoptosis of hematopoietic tumor cells. Additionally, pomalidomide inhibited the proliferation of lenalidomide-resistant multiple myeloma cell lines and synergized with dexamethasone in both lenalidomide-sensitive and lenalidomide-resistant cell lines to induce tumor cell apoptosis. Pomalidomide enhanced T cell- and natural killer (NK) cell-mediated immunity and inhibited production of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. Pomalidomide demonstrated anti-angiogenic activity in a mouse tumor model and in the in vitro umbilical cord model. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Aging (Phase 2)
Amyloid (Phase 2)
Amyloidosis (Phase 2)
Anemia, Sickle Cell (Phase 1)
Blood Protein Disorders (Phase 2)
Burkitt Lymphoma (Phase 1)
Carcinoma, Small Cell (Phase 1/Phase 2)
Central Nervous System Neoplasms (Phase 2)
Chromosome Disorders (Phase 2)
Corneal Diseases (Phase 1/Phase 2)
Drugs, Generic (Phase 1)
Endoscopy (Phase 2)
Genetic Diseases, Inborn (Phase 2)
Glioma (Phase 1)
Graft vs Host Disease (Phase 2)
Healthy Volunteers (Phase 1)
Hematologic Diseases (Phase 2)
Hematologic Neoplasms (Phase 1)
Hematology (Phase 1/Phase 2)
HIV (Phase 2)
Hodgkin Disease (Phase 1)
Immunoglobulin Light-chain Amyloidosis (Phase 2)
Immunoglobulin Light Chains (Phase 1)
Intraocular Lymphoma (Phase 1)
Kidney Failure, Chronic (Phase 2)
Leukemia, B-Cell (Phase 1)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Leukemia, Plasma Cell (Phase 2)
Lung Diseases, Interstitial (Phase 2)
Lymphoma (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 1/Phase 2)
Lymphoma, Non-Hodgkin (Phase 1)
Lymphoma, Primary Effusion (Phase 1/Phase 2)
Medulloblastoma (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 2)
Neoplasms (Phase 2)
Neoplasms by Histologic Type (Phase 2)
Neoplasms, Plasma Cell (Phase 2)
Neurofibromatosis 1 (Phase 1)
Pancreatic Neoplasms (Phase 1/Phase 2)
Paraproteinemias (Phase 2)
Pharmacology, Clinical (Phase 1)
Plasmablastic Lymphoma (Phase 1)
Plasmacytoma (Phase 2)
Polycythemia Vera (Phase 2)
Primary Myelofibrosis (Phase 3)
Prostatic Neoplasms (Phase 2)
Pulmonary Fibrosis (Phase 2)
Recurrence (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Kaposi (Phase 2)
Scleroderma, Systemic (Phase 2)
Squamous Intraepithelial Lesions (Phase 2)
Telangiectasia, Hereditary Hemorrhagic (Phase 2)
Therapeutic Equivalency (Phase 1)
Thrombocytosis (Phase 2)
Vascular Diseases (Phase 1)
Waldenstrom Macroglobulinemia (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
